FDA Keeping Surrogate Endpoint For Type 2 Diabetes Agent Approvals

FDA is resoundingly rejecting the suggestion that clinical outcomes be used as the standard of evidence for demonstrating efficacy for anti-diabetic agents, rather than the standard surrogate measure of glycemic control currently used

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet